Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
Not Applicable
Active, not recruiting
- Conditions
- Transthyretin Amyloid CardiomyopathyHeart Failure
- Registration Number
- NCT05896904
- Lead Sponsor
- Aarhus University Hospital Skejby
- Brief Summary
Clinical comparison of patients with transthyretin cardiac amyloidosis and patients with heart failure with reduced ejection fraction
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Age >65
- ATTRwt diagnosis for patients, either with DPD-scintigraphy or myocardiac biopsy
- informed consent
Exclusion Criteria
- Alder <65
- No ATTRwt diagnosis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method intraventricular wall thickness 1 year echocardiographic measurement
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms differentiate transthyretin cardiac amyloidosis from heart failure with reduced ejection fraction in NCT05896904?
How does echocardiography aid in distinguishing TTR amyloid cardiomyopathy from HFrEF in clinical trials?
What are the key biomarkers for early detection and prognosis of TTR cardiac amyloidosis compared to HFrEF?
Are there specific adverse events associated with echocardiography-based diagnosis in TTR amyloidosis patients?
What are the current therapeutic strategies for TTR amyloid cardiomyopathy and how do they compare to HFrEF treatments?
Trial Locations
- Locations (1)
Aarhus University Hospital
🇩🇰Aarhus, Denmark
Aarhus University Hospital🇩🇰Aarhus, Denmark